In order to evaluate the effect of Cyclosporin-A (CyA) at doses of 5 mg/kg per day in atopic dermatitis we studied clinical effects, immunoglobulin production, lymphocytes subset, immunphenotype and local cytokine production in seven patients before and after 3 months CyA therapy. Clinically CyA was very effective in eliminating pruritus, erythema and vescicles with no significant adverse side effects. Using flow cytometric analysis we demonstrated that CyA treatment restored an overexpression of circulating CD25-positive cells. Similar results have been recorded with HLA-DR expression. CyA normalized the number of CD29 cells which were reduced in the blood of patients before starting treatment. Furthermore, after treatment, several cytokin...
Purpose: To assess differential roles of inflammatory cells in pathophysiology of severe atopic kera...
Atopic dermatitis (AD) is a highly debilitating disease with significant health impacts worldwide. I...
Systemic therapy is required in patients with severe atopic dermatitis (AD) refractory to adequate t...
In order to evaluate the effect of Cyclosporin-A (CyA) at doses of 5 mg/kg per day in atopic dermati...
Treatment of atopic dermatitis is a most challenging problem of dermatology. Essential role is alloc...
BACKGROUND: The immune response in atopic dermatitis (AD) is thought to be driven by T-helper (Th) 2...
Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens...
AD skin is characterized by the infiltration of CD4+ T cells in the dermis and epidermis. Chemokines...
textabstractThe efficacy of cyclosporin (Sandimmun®) given in a daily dose of 5 mg/kg for 6 weeks in...
The aim of the study was to investigate immunological mechanisms in atopic dermatitis. Serum IgE lev...
Cyclosporine A (CsA) is effective in treating moderate-to-severe atopic dermatitis (AD). This system...
We have studied two reducing-dose regimens intended to minimize toxicity of cyclosporin A (CyA) whil...
In the past decennia systemic immunosuppressive treatment options in moderate to severe atopic derma...
Introduction . Despite the progress that has been made in the therapy of atopic dermatitis in recent...
Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens...
Purpose: To assess differential roles of inflammatory cells in pathophysiology of severe atopic kera...
Atopic dermatitis (AD) is a highly debilitating disease with significant health impacts worldwide. I...
Systemic therapy is required in patients with severe atopic dermatitis (AD) refractory to adequate t...
In order to evaluate the effect of Cyclosporin-A (CyA) at doses of 5 mg/kg per day in atopic dermati...
Treatment of atopic dermatitis is a most challenging problem of dermatology. Essential role is alloc...
BACKGROUND: The immune response in atopic dermatitis (AD) is thought to be driven by T-helper (Th) 2...
Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens...
AD skin is characterized by the infiltration of CD4+ T cells in the dermis and epidermis. Chemokines...
textabstractThe efficacy of cyclosporin (Sandimmun®) given in a daily dose of 5 mg/kg for 6 weeks in...
The aim of the study was to investigate immunological mechanisms in atopic dermatitis. Serum IgE lev...
Cyclosporine A (CsA) is effective in treating moderate-to-severe atopic dermatitis (AD). This system...
We have studied two reducing-dose regimens intended to minimize toxicity of cyclosporin A (CyA) whil...
In the past decennia systemic immunosuppressive treatment options in moderate to severe atopic derma...
Introduction . Despite the progress that has been made in the therapy of atopic dermatitis in recent...
Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens...
Purpose: To assess differential roles of inflammatory cells in pathophysiology of severe atopic kera...
Atopic dermatitis (AD) is a highly debilitating disease with significant health impacts worldwide. I...
Systemic therapy is required in patients with severe atopic dermatitis (AD) refractory to adequate t...